Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Feb 23:12:631539.
doi: 10.3389/fimmu.2021.631539. eCollection 2021.

Identification of a Novel Serum Proteomic Signature for Primary Sjögren's Syndrome

Guillaume Padern  1 , Claire Duflos  2 , Rosanna Ferreira  1 , Said Assou  1 , Philippe Guilpain  1   3 , Alexandre Thibault Jacques Maria  1   3 , Radjiv Goulabchand  4 , Pascale Galea  5 , Maja Jurtela  2 , Christian Jorgensen  1 , Yves-Marie Pers  1
Affiliations

Identification of a Novel Serum Proteomic Signature for Primary Sjögren's Syndrome

Guillaume Padern et al. Front Immunol. .

Abstract

Context: Primary Sjögren's syndrome (pSS) is a complex heterogeneous autoimmune disease (AID) which can mimic rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE). Our exploratory study investigated serum biomarkers that may discriminate pSS from RA and SLE.

Methods: Serum concentrations of 63 biomarkers involved in immune cell trafficking, inflammatory response, cellular movement, and cell-to-cell signaling were measured in AID patients, included prospectively into the study at the Montpellier University Hospital. A multivariate analysis by multiple logistic regression was performed, and discriminative power assessed using logistic regression adjusted on significant demographic factors.

Results: Among the 95 patients enrolled, 42 suffered from pSS, 28 from RA, and 25 from SLE. Statistical analysis showed that concentrations of BDNF (OR = 0.493 with 95% CI [0.273-0.891]; p = 0.0193) and I-TAC/CXCL11 (OR = 1.344 with 95% CI [1.027-1.76]; p = 0.0314) can significantly discriminate pSS from RA. Similarly, greater concentrations of sCD163 (OR = 0.803 with 95% CI [0.649-0.994]; p = 0.0436), Fractalkine/CX3CL1 (OR = 0.534 with 95% CI [0.287-0. 991]; p = 0.0466), MCP-1/CCL2 (OR = 0.839 with 95% CI [0.732-0.962]; p = 0.0121), and TNFa (OR = 0.479 with 95% CI [0.247-0.928]; p = 0.0292) were associated with SLE diagnosis compared to pSS. In addition, the combination of low concentrations of BDNF and Fractalkine/CX3CL1 was highly specific for pSS (specificity 96.2%; positive predictive value 80%) compared to RA and SLE, as well as the combination of high concentrations of I-TAC/CXCL11 and low concentrations of sCD163 (specificity 98.1%; positive predictive value 75%).

Conclusion: Our study highlights biomarkers potentially involved in pSS, RA, and SLE pathophysiology that could be useful for developing a pSS-specific diagnostic tool.

Keywords: biomarkers; primary Sjögren syndrome; proteomics; rheumatoid arthritis; systemic lupus erythematosus.

PubMed Disclaimer

Conflict of interest statement

PGa was employed by company BioRad. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Heatmap representing the classification of diseases and functions by ingenuity pathway analysis (IPA). The visualization is a hierarchical heat map of functional categories generated by IPA software in which the major boxes represent a family (or category) of related functions. Within each box, each individual rectangle is a sub-function linked to the biological function of a group of proteins. The size of a rectangle is correlated with increasing overlap significance among the proteins members of the related function and the query proteins. The color scheme shown is based on z-scores, with activation in orange, inhibition in blue and undetermined functions in gray. Darker shades indicate higher absolute z-score heat map. For instance, most ‘Inflammatory response’, ‘Cellular movement’, ‘Immune cell trafficking’, ‘Cell-to-cell signaling and interaction’, ‘Hematological system development and function’ proteins were over-represented.
Figure 2
Figure 2
Functional and upstream regulatory networks. The most significant networks included proteins related to: (A) Cell-to-cell signaling and interaction, and cellular movement, (B) immune cell trafficking and inflammatory response, (C) organismal functions, hematological disease, and metabolic disease, (D, E) top-scoring network of regulator effects activated in the list of 63 biomarkers. Protein interaction networks were constructed using the ingenuity pathway analysis (IPA) software. Nodes shaded in pink represent proteins present in the list of 63 biomarkers; red nodes are proteins that are CXCL11 (I-TAC), CX3CL1 (Fractalkine), Brain Derived Neurotrophic Factor (BDNF), and sCD163; and proteins that are not found in the list of 63 biomarkers are in white. Dotted lines indicate indirect molecular interactions between proteins and continuous lines between nodes indicate direct functional interactions between connected proteins. Orange lines lead to activation.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Theander E, Jacobsson LTH. Relationship of Sjögren’s syndrome to other connective tissue and autoimmune disorders. Rheum Dis Clin North Am (2008) 34(4):935–47, viii–ix. 10.1016/j.rdc.2008.08.009 - DOI - PubMed
    1. Shiboski CH, Shiboski SC, Seror R, Criswell LA, Labetoulle M, Lietman TM, et al. . American College of Rheumatology/European League Against Rheumatism Classification Criteria for Primary Sjögren’s Syndrome: A Consensus and Data-Driven Methodology Involving Three International Patient Cohorts. Arthritis Rheumatol (2016. 2017) 69(1):35–45. 10.1002/art.39859 - DOI - PMC - PubMed
    1. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, et al. . Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheumatol (2010. 2010) 62(9):2569–81. - PubMed
    1. Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, et al. . European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Ann Rheum Dis (2019. 2019) 78(9):1151–9. 10.1136/annrheumdis-2018-214819 - DOI - PubMed
    1. McDonagh JE, Isenberg DA. Development of additional autoimmune diseases in a population of patients with systemic lupus erythematosus. Ann Rheum Dis (2000) 59(3):230–2. 10.1136/ard.59.3.230 - DOI - PMC - PubMed